BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$13.62
−1.94%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.61
- Revenue estimate
- $70.0M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.91
- EPS estimate
- -$0.76
- Revenue actual
- —
- Revenue estimate
- $490.5K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 10
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -21.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $15
- PT range
- $10 – $19
- Analysts
- 4
1 Buy2 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.76 | -$0.91 | Miss -19.58% | — |
| May 4, 2026 | -$0.86 | -$0.88 | Miss -2.33% | — |
| Mar 3, 2025 | -$1.56 | -$1.85 | Miss -18.59% | — |
| May 9, 2024 | -$1.50 | -$2.20 | Miss -46.67% | — |
| Feb 29, 2024 | -$1.41 | -$1.81 | Miss -28.37% | — |
| Nov 14, 2023 | -$1.33 | -$1.50 | Miss -12.78% | — |
| May 12, 2023 | -$1.39 | -$1.03 | Beat 25.90% | — |
| Mar 23, 2023 | -$1.24 | -$3.32 | Miss -167.74% | $215.1M |
| Nov 9, 2022 | -$2.53 | -$1.75 | Beat 30.83% | — |
| Aug 5, 2022 | -$2.79 | -$6.21 | Miss -122.58% | $215.1M |
| Feb 25, 2022 | -$2.07 | -$3.01 | Miss -45.41% | $190.0M |
| Mar 1, 2021 | -$2.89 | -$3.62 | Miss -25.26% | $35.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026